Crossbow Therapeutics Snares $77M in Series B
Vcnewsdaily·2026-03-18 19:26
Crossbow Therapeutics Snares $77M in Series B Back to Home Tweet CAMBRIDGE, MA, Crossbow Therapeutics, a biotechnology company developing a novel class of potent and precise antibody therapies, has raised $77 million in a Series B financing. Crossbow Therapeutics, a biotechnology company developing a novel class of potent and precise antibody therapies to treat a broad range of cancers, announced it has raised $77 million in a Series B financing that will support the completion of the CROSSCHECK-001 P ...